(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Verastem's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast VSTM's revenue for 2025 to be $854,557,708, with the lowest VSTM revenue forecast at $252,954,950, and the highest VSTM revenue forecast at $1,923,216,485. On average, 3 Wall Street analysts forecast VSTM's revenue for 2026 to be $2,386,705,840, with the lowest VSTM revenue forecast at $1,687,968,381, and the highest VSTM revenue forecast at $3,650,898,793.
In 2027, VSTM is forecast to generate $4,851,068,849 in revenue, with the lowest revenue forecast at $3,832,520,447 and the highest revenue forecast at $5,792,668,355.